Single oral dose acute and subacute toxicity of a c-MET tyrosine kinase inhibitor and CDK 4/6 inhibitor combination drug therapy

c-MET inhibitor, crizotinib, and CDK 4/6 inhibitor, palbociclib, have been evaluated in combination as cancer treatment in vitro. Because the toxicological data for the combination of these drugs is limited, we investigated the toxicity of the crizotinib and palbociclib combination in 80 ICR (CD-1)...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Cancer Res
Hlavní autoři: Smith, Brian, Hsu, Yi-Hsin, Flores, Rene, Gagea, Mihai, Craig, Suzanne, Hung, Mien-Chie
Médium: Artigo
Jazyk:Inglês
Vydáno: e-Century Publishing Corporation 2018
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5794732/
https://ncbi.nlm.nih.gov/pubmed/29416931
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky